![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
CHARACTERIZATION OF SINGLE VERSUS DUAL ACTIVE MONOCLONAL ANTIBODIES AGAINST SARS-COV-2
|
|
|
CROI 2023 Feb 20-23
Manish C. Choudhary
Brigham and Women's Hospital | Harvard Medical School Boston, MA, USA
there are ongoing efforts to develop the next generation of mAbs and this study shows proof-of-principle that dual-active mAb therapy offers virologic benefit over single-active mAbs. This will help inform the design and implementation for future mAb therapeutics.
![0305231](../images/030523/032523-16/0305231.gif)
![0305232](../images/030523/032523-16/0305232.gif)
![0305233](../images/030523/032523-16/0305233.gif)
![0305234](../images/030523/032523-16/0305234.gif)
![0305235](../images/030523/032523-16/0305235.gif)
![0305236](../images/030523/032523-16/0305236.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|